Barbara Pistilli, MD is the chair of the breast cancer unit at Gustave Roussy since March 2021. The clinical activity of Breast Cancer Group encloses around 2000 new patients and 700 inclusions in clinical trials, yearly. The goal of the group is to provide groundbreaking and patient-centered strategies that cover all steps from breast cancer prevention to development of innovative treatment strategies and survivorship care. The scientific strategy is driven by the integration between translational and clinical sciences in a limited number of large comprehensive programs, where knowledge in biology drives clinical development and patient samples feed translational research. In this regard, she leads a large translational program focusing on identification of mechanisms of response and resistance to antibody drug conjugates which include a number of phase I and II trials based on diverse treatment strategies in patients with metastatic breast and lung cancer, with a large sample collection for exploratory biomarker analysis.

Dr Barbara Pistilli has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Seagen, Gilead, Novartis, Lilly, MSD, Pierre Fabre, Daiichi Sankyo, Olema and Pfizer